2024 Financial Outlook
"Based on our solid first quarter financial performance and our expectations for stronger revenue growth in the second half of the year, we reaffirm our 2024 financial guidance," concluded Ms. Weber.
| ($ in millions) | Previously Reported 2024 Guidance Ranges |
| Revenue | $200-$204 |
| Adjusted EBITDA1 | $60-$63 |
Save time and jump to the most important pieces.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 2/20/2024 | $9.00 | Buy | B. Riley Securities |
| 2/1/2024 | Buy | Jefferies |
Duke University Oncologist and former Optum Executive Dr. Yousuf Zafar Named Chief Medical OfficerVeteran Digital Health and Commercial Leader Peter Bridges to Serve as Chief Strategy and Growth OfficerDebra Morris Promoted to PresidentDUARTE, Calif., Nov. 13, 2024 /PRNewswire/ -- AccessHope, LLC, a company changing the way leading-edge cancer expertise is delivered, today announced that it is expanding its executive leadership team in response to growing demand for the company's personalized cancer benefit and upcoming product expansion. Yousuf Zafar, MD, MHS, a widely published practicing oncologist from Duke University who brings expertise in value-based care and precision medicine, will
Continued Profitable Growth Vertical integration drives gross profit margin improvement Launch of proprietary clinical decision support software to strengthen competitive advantages Biote (NASDAQ:BTMD), a leading solutions provider in preventive health care through the delivery of personalized hormone optimization and therapeutic wellness, today announced financial results for the third quarter ended September 30, 2024. Third Quarter 2024 Financial Highlights (All financial result comparisons made are against the prior-year period) Revenue of $51.4 million Procedure revenue of $37.9 million Gross profit margin of 70.5% Net income of $12.7 million and diluted earnings per
biote Corp. (NASDAQ:BTMD) ("Biote" or the "Company"), a leading solutions provider in preventive health care through the delivery of personalized hormone optimization and therapeutic wellness, today announced the Company will provide third quarter financial results on Tuesday, November 12, 2024, after the close of the market. A conference call to discuss the firm's results will be held at 5:00 p.m. ET. the same day. Conference Call Details The conference call may be accessed by dialing (844) 481-2820 (U.S toll-free) or (412) 317-0679 (International). The live webcast of the call can be accessed using the following link: biote Corp. Third Quarter Earnings Call. A replay of the webcast will
Strategic and accretive transaction enables vertical integration of hormone product manufacturing biote Corp. (NASDAQ:BTMD) ("Biote" or the "Company"), a leading solutions provider in preventive health care through the delivery of personalized hormone optimization and therapeutic wellness, today announced a definitive agreement to acquire F.H. Investments, Inc., d/b/a Asteria Health, a privately held 503B manufacturer of compounded bioidentical hormones. The company operates an FDA-registered 503B outsourcing facility in Birmingham, Alabama and currently supports Biote-certified practitioners and Biote-partnered clinics in numerous U.S. states. Through this transaction, Biote is strengt
biote Corp. (NASDAQ:BTMD) ("Biote" or the "Company"), a leading solutions provider in preventive health care through the delivery of personalized hormone optimization and therapeutic wellness, today announced that Robert Peterson has been named Chief Financial Officer, effective January 8, 2024. Mr. Peterson will lead Biote's finance operations, including accounting and controllership, financial planning and analysis, financial reporting, internal audit, tax, treasury and investor relations. Mr. Peterson succeeds Samar Kamdar, who is transitioning to pursue other opportunities, but will remain as an advisor to the Company during a transition period. Mr. Kamdar's transition is unrelated to t
Ms. Puncochar to Drive Execution of Biote's Strategic Sales and Marketing Initiatives biote Corp. (NASDAQ:BTMD) ("Biote" or the "Company"), a leading solutions provider in preventive health care through the delivery of personalized hormone therapy, today announced the appointment of Mary J. Puncochar as Chief Commercial Officer. In this role, Ms. Puncochar will lead Biote's commercial initiatives to expand the Company's presence in the growing market for hormone replacement therapy. Ms. Puncochar joins Biote with more than 30 years of experience in sales, tech-enabled marketing and management roles at leading healthcare, pharmaceutical and medical device companies. Prior to joining Biot
SC 13G/A - biote Corp. (0001819253) (Subject)
SC 13G/A - biote Corp. (0001819253) (Subject)
SC 13G/A - biote Corp. (0001819253) (Subject)
424B3 - biote Corp. (0001819253) (Filer)
424B3 - biote Corp. (0001819253) (Filer)
10-Q - biote Corp. (0001819253) (Filer)
B. Riley Securities initiated coverage of biote Corp. with a rating of Buy and set a new price target of $9.00
Jefferies initiated coverage of biote Corp. with a rating of Buy
4 - biote Corp. (0001819253) (Issuer)
4 - biote Corp. (0001819253) (Issuer)
4/A - biote Corp. (0001819253) (Issuer)
For $60 million in the aggregate, Biote will repurchase all of the approximately 8.3 million of the Paired Interests and/or Class A Shares, as applicable, owned by Ms. Donovitz and will release and cancel all of the approximately 4.0 million Paired Interests subject to contractual earnout provisions ("earnout shares") owned by Ms. Donovitz for no additional monetary consideration. Biote intends to fund the repurchases in accordance with its existing capital allocation strategy.
2024 Financial Outlook"Based on our solid first quarter financial performance and our expectations for stronger revenue growth in the second half of the year, we reaffirm our 2024 financial guidance," concluded Ms. Weber.($ in millions)Previously Reported 2024 Guidance RangesRevenue$200-$204Adjusted EBITDA1$60-$63
Continued Profitable Growth Vertical integration drives gross profit margin improvement Launch of proprietary clinical decision support software to strengthen competitive advantages Biote (NASDAQ:BTMD), a leading solutions provider in preventive health care through the delivery of personalized hormone optimization and therapeutic wellness, today announced financial results for the third quarter ended September 30, 2024. Third Quarter 2024 Financial Highlights (All financial result comparisons made are against the prior-year period) Revenue of $51.4 million Procedure revenue of $37.9 million Gross profit margin of 70.5% Net income of $12.7 million and diluted earnings per
biote Corp. (NASDAQ:BTMD) ("Biote" or the "Company"), a leading solutions provider in preventive health care through the delivery of personalized hormone optimization and therapeutic wellness, today announced the Company will provide third quarter financial results on Tuesday, November 12, 2024, after the close of the market. A conference call to discuss the firm's results will be held at 5:00 p.m. ET. the same day. Conference Call Details The conference call may be accessed by dialing (844) 481-2820 (U.S toll-free) or (412) 317-0679 (International). The live webcast of the call can be accessed using the following link: biote Corp. Third Quarter Earnings Call. A replay of the webcast will
Procedure revenue growth accelerates sequentially BioteRx roll-out on track with further expansion planned Management reiterates 2024 financial guidance Biote (NASDAQ:BTMD), a leading solutions provider in preventive health care through the delivery of personalized hormone optimization and therapeutic wellness, today announced financial results for the second quarter ended June 30, 2024. Second Quarter 2024 Financial Highlights (All financial result comparisons made are against the prior-year period) Revenue of $49.2 million Procedure revenue of $38.4 million Gross profit margin of 68.9%, including a $1.2 million inventory step-up related to the acquisition of Asteria Healt